(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
about
Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiologyMETastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerPrediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CTDiagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.PET Tracers Beyond FDG in Prostate Cancer.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Therapy assessment in prostate cancer using choline and PSMA PET/CT.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomyPreliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.Positron emission tomography in prostate cancer: An update on state of the art
P2860
Q28071705-22B51422-145C-4E64-A138-7F8C49DDCB78Q31108842-C72B868D-6089-4D4A-8E4D-1FF47E86498CQ35925260-227AC320-FB1F-4908-ADE2-DDAE0F6B2210Q37496697-E4370E03-DA23-44BA-8A94-34608FFA7265Q38766102-8963A075-7349-49D6-9375-0042E6437C88Q38804450-C5ABB17F-492D-4D17-9887-1F12DDAE3245Q39003086-E6552CD9-035B-474D-92A3-D0C50DE79AADQ39242140-C4261723-9640-4CF4-AD83-781A7C33D76CQ39328036-0138D481-C8F9-46A6-BE95-DC9A5D3D4401Q39699773-FD0CF2B4-648C-4D65-A637-56FE5840E0D9Q40634245-864FB644-1385-4543-B707-56A9B996177BQ42319922-BDBD61AD-F1B1-427F-A5E3-C44DC4B49926Q47399411-1F252357-C352-48AB-992A-68763AF3048BQ47645575-690E7AE4-6870-4686-937C-0103D087FDA5Q52982270-4FF71918-2679-4F37-93DB-1330D687FD04Q53772593-AC2750B7-D8B1-46F8-B0C4-EF33721F79E2Q57110351-8DBD1F30-13E1-459B-8A51-AD0F196876CF
P2860
(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
(11)C-Choline PET/CT in castra ...... tients treated with docetaxel.
@en
type
label
(11)C-Choline PET/CT in castra ...... tients treated with docetaxel.
@en
prefLabel
(11)C-Choline PET/CT in castra ...... tients treated with docetaxel.
@en
P2093
P2860
P1476
(11)C-Choline PET/CT in castra ...... atients treated with docetaxel
@en
P2093
Andrea Ardizzoni
Eugenio Brunocilla
Marco Borghesi
Paolo Castellucci
Piergiorgio Di Tullio
Riccardo Renzi
Riccardo Schiavina
Tiziano Graziani
P2860
P2888
P356
10.1007/S00259-015-3177-4
P577
2015-09-01T00:00:00Z